PIPELINE
CIS BIOPHARMA's cutting-edge pipeline targets aggressive cancers with high unmet needs, focusing on small cell lung cancer, SCLC, glioblastoma multiforme, GBM, and brain metastases, BM. Our innovative technologies leverage novel targets and modalities to combat these devastating diseases, characterized by poor prognoses and limited treatment options.
CBO-001 targeting
lung cancer, SCLC
Our lead program offers renewed hope for patients facing incurable lung cancer, specifically the highly aggressive small cell lung cancer, SCLC.
This advanced antibody-drug conjugate, ADC, targets CD 171, also known as L1 surface molecule. The proprietary monoclonal antibody comprises state-of-the-art topo-isomerase-I-inhibitors attached by cleavable linkers.
CBO-002 targeting
brain metastases, BM
CBO-002 is engineered to overcome the limitations of cancer therapies in treating brain metastases, primarily associated with lung and breast cancers.
This innovative nanobody-drug conjugate, NDC, targets CD 276, also known as B7H3 surface molecule. The proprietary nanobody comprises state-of-the-art topo-isomerase-I-inhibitors attached by cleavable linkers.
CBO-003 targeting
glioblastoma, GBM
CBO-003 is designed to overcome the defense mechanisms of glioblastoma multiforme, GBM, an aggressive primary brain tumor with unmet need.
This novel nanobody-radionuclide conjugate or radioligand therapy, RLT, targets CD 276, also known as B7H3 surface molecule. The nanobody comprises state-of-the-art radionuclides attached by DOTA chelators.
Discovery >>> Optimization >>> Preclinical >>> Phase I >>> Phase II >>> Phase III
Discovery Optimization Preclinical Phase l-III
CBO-001 - ADC - CD 171 - Topo-I
CBO-002 - NDC - CD 276 - Topo-I
CD276 Topo-I
CBO-003 - NRC - CD 276 - Isotope
CD276 isotope
